340
Participants
Start Date
July 29, 2025
Primary Completion Date
April 23, 2026
Study Completion Date
July 17, 2026
RO7795081
RO7795081 will be administered orally once daily, according to the randomized dosing regimen, during the 38-week treatment period.
Placebo
Placebo matching each RO7795081 dosing regimen arm will be administered orally once daily during the 38-week treatment period.
Neurobehavioral Research, Inc., Cedarhurst
Tristar Clinical Investigations, Philadelphia
Emerson Clinical Research Institute LLC, Washington D.C.
Manassas Clinical Research Center, Manassas
Accellacare Research of Winston Salem, Winston-Salem
Accellacare of Cary - Cary Medical Group, Cary
Accellacare of Cary, Cary
Accellacare of Raleigh, Raleigh
Accellacare of Rocky Mount, Rocky Mount
Accellacare of Salisbury, Salisbury
Accellacare of Wilmington, LLC, Wilmington
Accellacare - Hickory, Hickory
Accellacare of Piedmont Healthcare, Statesville
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City
K2 Medical Research - The Villages, Lady Lake
K2 Medical Research-Maitland, Maitland
K2 Medical Research South Orlando, LLC, Orlando
Pinnacle Research Group, Anniston
Clinical Research Associates, Nashville
Internal Medicine and Pediatrics Associates of Bristol, Bristol
Alliance for Multispecialty Research. LLC, Knoxville
Accellacare of Knoxville, Knoxville
Knoxville-Summit-Halls Family Practice, Knoxville
McFarland Clinic under Accellacare, Ames
Mercury Street Medical Group, PLLC, Butte
Alliance for Multispecialty Research, LLC (AMR Norman), Norman
Velocity Clinical Research, Dallas
Juno Research, LLC, Houston
Apex Mobile Clinical Research, Bellaire
Consano Clinical Research, Shavano Park
Texas Diabetes & Endocrinology, P.A., Austin
Chrysalis Clinical Research, St. George
Asclepes Research Centers, Sherman Oaks
Prospective Research Innovations Inc., Rancho Cucamonga
Encompass Clinical Research, Spring Valley
Orange County Research Center, Lake Forest
Chase Medical Research, Waterbury
Hoffmann-La Roche
INDUSTRY